Why is Hims & Hers Health stock sliding today?
Hims & Hers Health shares fell about 1.5% in after-hours after Q2 2026 results. Revenue rose to $753M (+38% YoY) but EPS was a loss of -$0.37 versus -$0.05 expected, tied to gross margin contracting 12 points from a shift from compounded to branded GLP-1. The company raised FY2026 revenue to $3.1B-$3.3B and Q3 guidance to $880M-$900M, but legal and regulatory overhangs and softer GLP-1 billing weighed.
How this was made
The 30-second read
Why it matters
Investors are repricing the near-term profitability outlook after a large EPS miss and gross margin contraction, even as full-year and Q3 revenue guidance improves.
Market read
A concrete earnings and guidance print plus margin and billing details explain the stock’s after-hours weakness and set up a near-term debate on whether revenue growth can offset profitability pressure.
What to watch
The article notes unresolved regulatory and legal risks and softening GLP-1 billing data; traders may be over-weighting near-term billing declines versus longer-term branded GLP-1 ramp.
Background
Hims & Hers is transitioning GLP-1 weight-loss medications from compounded to branded formulations, which the company links to margin pressure.
Ticker impact
Hims & Hers reported Q2 2026 results with an EPS loss of -$0.37 despite a $753M revenue beat, and guided full-year revenue higher.
Near-term downside risk remains despite higher revenue outlook, as investors focus on profitability pressure and GLP-1 billing momentum.
The article cites a wide EPS miss, 12-point gross margin contraction, and a small sequential decline in GLP-1 billings, which together outweigh the revenue guidance upgrade in the immediate reaction.
Market effects
Highlights investor sensitivity in GLP-1 weight-loss platforms to gross margin and billing momentum during product mix transitions.
Limited, as the broader S&P 500, Dow, and Nasdaq were flat to slightly lower.
Primarily company-specific; no direct global macro catalyst beyond general risk sentiment.
Counterpoint
The guidance upgrade and revenue beat may indicate demand resilience, so the EPS/margin shock could be transitional rather than structural.
Key entities
- companyHims & Hers Health
Subject of the article, with Q2 2026 earnings miss, margin compression, and upgraded revenue guidance driving the after-hours move.
- regulatorFederal Trade Commission
Filed a late-July lawsuit alleging sensitive user health data was shared with third-party advertising platforms, cited as an ongoing sentiment overhang.
- analyst_firmTruist Securities
Reiterated a Hold rating with a $27 price target, reflecting a cautious stance despite the guidance upgrade.
